Scholarlink

Background <p>Osteoporosis is prevalent among postmenopausal women and is characterized by excessive bone resorption primarily mediated by osteoclasts. This study aimed to investigate the effects of the natural compound Licochalcone D (Lico D) on osteoclast differentiation and its therapeutic potential in ovariectomized (OVX) mouse models of osteoporosis.</p> Methods <p>The cytotoxicity of various doses of Lico D on mouse bone marrow-derived macrophages (BMMs) was evaluated using CCK-8 assays. The differentiation of BMMs into osteoclasts was induced by RANKL treatment, followed by exposure to Lico D at doses of 2, 4, and 8&#xa0;µg/ml. Additionally, 10 µM BAY 11-7821 (an NF-κB inhibitor) was used to inhibit NF-κB signaling in RANKL-stimulated BMMs. TRAP staining was conducted to measure osteoblast cell number. Western blot analysis was performed to measure protein levels of osteoclast differentiation markers and NF-κB-related factors. RT-qPCR was performed to assess the mRNA levels of downstream genes in the NF-κB pathway. In animal experiments, OVX mice received intraperitoneal injections of Lico D at doses of 10 or 50&#xa0;mg/kg. Subsequently, femurs were harvested for histopathological examination.</p> Results <p>Lico D at doses of 2–8&#xa0;µg/ml showed no significant cytotoxicity toward BMMs. In addition, Lico D inhibited RANKL-induced osteoclast formation and downregulated protein levels of osteoclast-specific genes (mmp9, ctsk, c-Fos and nfatc1). Moreover, Lico D suppressed the phosphorylation of NF-κB p65 and IκBα in RANKL-treated BMMs. Importantly, the suppressive effects of Lico D, especially at 8&#xa0;µg/ml, on osteoclast cell number and osteoclast-specific markers were comparable to BAY 11-7821. Moreover, Lico D inhibited OVX-induced bone loss and restored dysregulated bone parameters in mice.</p> Conclusion <p>Lico D inhibits RANKL-induced osteoclast differentiation and alleviates postmenopausal osteoporosis in mice by suppressing the NF-κB signaling pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Licochalcone D inhibits osteoclast differentiation and postmenopausal osteoporosis by inactivating the NF-κB signaling pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Xiaoyi Shen,
  • Qian Zhang,
  • Jingjing Ding,
  • Jun Zhou,
  • Sasa Tan,
  • Xianzhen Feng,
  • Zhongqing Xu,
  • Fei Hua

摘要

Background

Osteoporosis is prevalent among postmenopausal women and is characterized by excessive bone resorption primarily mediated by osteoclasts. This study aimed to investigate the effects of the natural compound Licochalcone D (Lico D) on osteoclast differentiation and its therapeutic potential in ovariectomized (OVX) mouse models of osteoporosis.

Methods

The cytotoxicity of various doses of Lico D on mouse bone marrow-derived macrophages (BMMs) was evaluated using CCK-8 assays. The differentiation of BMMs into osteoclasts was induced by RANKL treatment, followed by exposure to Lico D at doses of 2, 4, and 8 µg/ml. Additionally, 10 µM BAY 11-7821 (an NF-κB inhibitor) was used to inhibit NF-κB signaling in RANKL-stimulated BMMs. TRAP staining was conducted to measure osteoblast cell number. Western blot analysis was performed to measure protein levels of osteoclast differentiation markers and NF-κB-related factors. RT-qPCR was performed to assess the mRNA levels of downstream genes in the NF-κB pathway. In animal experiments, OVX mice received intraperitoneal injections of Lico D at doses of 10 or 50 mg/kg. Subsequently, femurs were harvested for histopathological examination.

Results

Lico D at doses of 2–8 µg/ml showed no significant cytotoxicity toward BMMs. In addition, Lico D inhibited RANKL-induced osteoclast formation and downregulated protein levels of osteoclast-specific genes (mmp9, ctsk, c-Fos and nfatc1). Moreover, Lico D suppressed the phosphorylation of NF-κB p65 and IκBα in RANKL-treated BMMs. Importantly, the suppressive effects of Lico D, especially at 8 µg/ml, on osteoclast cell number and osteoclast-specific markers were comparable to BAY 11-7821. Moreover, Lico D inhibited OVX-induced bone loss and restored dysregulated bone parameters in mice.

Conclusion

Lico D inhibits RANKL-induced osteoclast differentiation and alleviates postmenopausal osteoporosis in mice by suppressing the NF-κB signaling pathway.